

# Mario Masarone

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7444465/mario-masarone-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80  
papers

1,906  
citations

21  
h-index

41  
g-index

114  
ext. papers

2,402  
ext. citations

3.8  
avg, IF

4.87  
L-index

#	Paper	IF	Citations
80	Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of Southern Italy in the province of Salerno.. <i>Liver International</i> , <b>2022</b> ,	7.9	0
79	A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort.. <i>Hepatology</i> , <b>2021</b> ,	11.2	3
78	PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 734847	4.9	4
77	The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	13
76	The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	11
75	Characterisation of asymptomatic patients and efficacy of preventive measures for SARS-CoV-2 infection in a large population of Southern Italy: a cohort study. <i>BMJ Open</i> , <b>2021</b> , 11, e043112	3	
74	Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives. <i>Nutrients</i> , <b>2021</b> , 13,	6.7	4
73	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 677-681	3.3	7
72	Management of liver disease in Italy after one year of the SARS-CoV-2 pandemic: A web-based survey. <i>Liver International</i> , <b>2021</b> , 41, 2228-2232	7.9	4
71	Viral hepatitis: Milestones, unresolved issues, and future goals. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 4603-4638	5.6	3
70	Associated screening for HCV and SARS-Cov2 infection in an urban area of Southern Italy: A cohort study. <i>Journal of Viral Hepatitis</i> , <b>2021</b> ,	3.4	3
69	Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. <i>Metabolomics</i> , <b>2021</b> , 17, 12	4.7	16
68	Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 781567	4.9	0
67	The Bisphenol A Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	9
66	Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 541-546	3.3	8
65	The diagnostic conundrum in non-alcoholic fatty liver disease. <i>Exploration of Medicine</i> , <b>2020</b> , 1,	1.1	1
64	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 937-941	3.3	22

63	Screening, Linkage to Care and Treatment of Hepatitis C Infection in Primary Care Setting in the South of Italy. <i>Life</i> , <b>2020</b> , 10,	3	2
62	Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease. <i>International Journal of Environmental Research and Public Health</i> , <b>2019</b> , 16,	4.6	14
61	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. <i>International Journal of Environmental Research and Public Health</i> , <b>2019</b> , 16,	4.6	43
60	HCV point-of-care screening programme and treatment options for people who use drugs in a metropolitan area of Southern Italy. <i>Liver International</i> , <b>2019</b> , 39, 1845-1851	7.9	9
59	Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. <i>Liver International</i> , <b>2019</b> , 39, 1852-1859	7.9	21
58	Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: A systematic review and meta-analysis. <i>Liver International</i> , <b>2019</b> , 39, 1292-1306	7.9	21
57	Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2019</b> , 2019, 8742075	6.7	23
56	Real-life efficacy and safety of glecaprevir/pibrentasvir in HCV-infected patients with chronic kidney disease. <i>GastroHep</i> , <b>2019</b> , 1, 166	1	1
55	Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells. <i>Oncology Reports</i> , <b>2019</b> , 41, 1476-1486	3.5	20
54	HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 605-609		4
53	Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 826-837	6.1	29
52	Virological patterns of HCV patients with failure to interferon-free regimens. <i>Journal of Medical Virology</i> , <b>2018</b> , 90, 942-950	19.7	12
51	Pressure support ventilation vs Continuous positive airway pressure for treating of acute cardiogenic pulmonary edema: A pilot study. <i>Respiratory Physiology and Neurobiology</i> , <b>2018</b> , 255, 7-10	2.8	7
50	Metabolomics in the progression of non alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 18	3.3	2
49	Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma. <i>Hepatology</i> , <b>2018</b> , 67, 48-55	11.2	54
48	Lactate determination in pleural and abdominal effusions: a quick diagnostic marker of exudate-a pilot study. <i>Internal and Emergency Medicine</i> , <b>2018</b> , 13, 901-906	3.7	2
47	Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2018</b> , 2018, 9547613	6.7	284
46	Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 129-138	1.6	21

45	Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2018</b> , 2018, 2568569	6.7	14
44	"Non alcoholic fatty liver disease and eNOS dysfunction in humans". <i>BMC Gastroenterology</i> , <b>2017</b> , 17, 35	3	32
43	Adiponectin in hepatology. <i>Minerva Biotechnology and Biomolecular Research</i> , <b>2017</b> , 30,		3
42	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	9
41	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 427-434	18.8	13
40	Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis. <i>Nutrients</i> , <b>2017</b> , 9,	6.7	9
39	Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. <i>PLoS ONE</i> , <b>2017</b> , 12, e0178473	3.7	42
38	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185728	3.7	28
37	Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2017</b> , 26, 261-268	1.4	14
36	A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells. <i>In Vivo</i> , <b>2017</b> , 31, 609-618	2.3	12
35	Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , <b>2016</b> , 113, 179-86	7.4	5
34	Alcoholic Liver Disease and Hepatitis C Chronic Infection. <i>Reviews on Recent Clinical Trials</i> , <b>2016</b> , 11, 201-72	7.2	5
33	Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment. <i>Reviews on Recent Clinical Trials</i> , <b>2016</b> , 11, 159-66	1.2	17
32	HIV Vaccine for Prevention and Cure, A Mission Possible. <i>Reviews on Recent Clinical Trials</i> , <b>2016</b> , 11, 290-296	2.6	1
31	Epidemiology and Natural History of Alcoholic Liver Disease. <i>Reviews on Recent Clinical Trials</i> , <b>2016</b> , 11, 167-74	1.2	39
30	Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy. <i>Reviews on Recent Clinical Trials</i> , <b>2016</b> , 11, 306-316	1.2	4
29	Pharmacotherapy of alcoholic liver disease in clinical practice. <i>International Journal of Clinical Practice</i> , <b>2016</b> , 70, 119-31	2.9	19
28	The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction. <i>European Review for Medical and Pharmacological Sciences</i> , <b>2016</b> , 20, 4731-4741	2.9	30

27	Lung ultrasound for diagnosis of pneumonia in emergency department. <i>Internal and Emergency Medicine</i> , <b>2015</b> , 10, 851-4	3.7	36
26	HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?. <i>Annals of Hepatology</i> , <b>2015</b> , 14, 325-332	3.1	2
25	Helicobacter pylori infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. <i>United European Gastroenterology Journal</i> , <b>2015</b> , 3, 17-24	5.3	50
24	Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. <i>Hepatitis Monthly</i> , <b>2015</b> , 15, e18640	1.8	6
23	HCV antiviral therapy in injection drug users: difficult to treat or easy to cure?. <i>Annals of Hepatology</i> , <b>2015</b> , 14, 325-32	3.1	
22	The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. <i>BMC Research Notes</i> , <b>2014</b> , 7, 59	2.3	6
21	Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. <i>BMC Gastroenterology</i> , <b>2014</b> , 14, 31	3	21
20	Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 16841-57	5.6	31
19	Diaphragmatic motility assessment in COPD exacerbation, early detection of Non-Invasive Mechanical Ventilation failure: a pilot study. <i>The Ultrasound Journal</i> , <b>2014</b> , 6,		5
18	Etiology of newly-diagnosed cases of chronic liver disease in Southern Italy: results of a prospective multicentric study. <i>Italian Journal of Medicine</i> , <b>2014</b> , 8, 176	0.5	2
17	Non alcoholic fatty liver: epidemiology and natural history. <i>Reviews on Recent Clinical Trials</i> , <b>2014</b> , 9, 126-33		176
16	Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 15233-40	5.6	50
15	Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. <i>Medical Hypotheses</i> , <b>2013</b> , 81, 913-5	3.8	15
14	Coeliac disease and C virus-related chronic hepatitis: a non association. <i>BMC Research Notes</i> , <b>2012</b> , 5, 533	2.3	8
13	HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. <i>Acta Diabetologica</i> , <b>2011</b> , 48, 337-343	3.9	20
12	Antiviral therapy: why does it fail in HCV-related chronic hepatitis?. <i>Expert Review of Anti-Infective Therapy</i> , <b>2011</b> , 9, 535-43	5.5	16
11	Indirect markers of non-alcoholic fatty liver disease: Another piece of the puzzle?. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 846-7	3.3	1
10	Inferior vena cava collapsibility to guide fluid removal in slow continuous ultrafiltration: a pilot study. <i>Intensive Care Medicine</i> , <b>2010</b> , 36, 692-6	14.5	47

9	Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 462-6	5.6	20
8	The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 3159-66	0.7	15
7	Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin lymphoma. <i>Journal of Hepatology</i> , <b>2008</b> , 49, 557-63	13.4	62
6	Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease. <i>Journal of Viral Hepatitis</i> , <b>2007</b> , 14, 714-20	3.4	7
5	Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients. <i>Gut</i> , <b>2007</b> , 56, 1470-1	19.2	11
4	The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. <i>Digestive and Liver Disease</i> , <b>2006</b> , 38, 485-9	3.3	228
3	Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. <i>Journal of Hepatology</i> , <b>2006</b> , 45, 779-85	13.4	46
2	Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. <i>Journal of Viral Hepatitis</i> , <b>2006</b> , 13, 290-6	3.4	39
1	Serum metabolomic profile of symptomatic and asymptomatic SARS-CoV-2 infected patients&nbsp;		3